Lotilaner (Credelio Cat)

Lotilaner, marketed as Credelio Cat, represents a groundbreaking advancement in feline ectoparasite control as the first and only FDA-approved oral flea and tick medication specifically designed for cats. This innovative isoxazoline compound is formulated as a small, flavored chewable tablet that provides convenient monthly protection against fleas and certain tick species. The development of an oral flea and tick option for cats addresses a significant unmet need, as many cat owners find topical applications challenging and cats often resist liquid treatments applied to their skin.

Lotilaner works through the same mechanism as other isoxazoline class medications, inhibiting gamma-aminobutyric acid (GABA)-gated chloride channels in the arthropod nervous system. This inhibition blocks chloride ion transfer across nerve cell membranes, causing uncontrolled neuromuscular activity that results in paralysis and death of fleas and ticks. The selective toxicity between arthropods and mammals stems from differential sensitivity of GABA receptors, with insect and acarine receptors being highly susceptible while mammalian GABA receptors remain largely unaffected at therapeutic doses.

Credelio Cat tablets are specifically formulated with attention to feline preferences and physiology. Recognizing that cats have fewer taste buds than dogs and rely heavily on smell when evaluating food, the tablets are designed with vanilla and yeast flavoring to encourage acceptance. The small tablet size facilitates easy administration either directly by mouth or hidden in food. In clinical studies, over ninety-nine percent of cat owners successfully administered Credelio Cat to their pets, demonstrating the product's high acceptance rate across diverse feline populations.

Credelio Cat is FDA-approved for the treatment and prevention of flea infestations in cats and kittens eight weeks of age and older weighing two pounds or greater. The medication is additionally approved for treatment and control of black-legged tick infestations in cats and kittens six months of age and older weighing two pounds or greater. The rapid onset of action, with flea killing beginning within six hours of administration, combined with month-long efficacy makes lotilaner an effective choice for both treating active infestations and maintaining ongoing protection against ectoparasites.

Lotilaner (Credelio Cat) is indicated for the treatment and prevention of flea infestations caused by Ctenocephalides felis, the cat flea, for one month in cats and kittens eight weeks of age and older weighing two pounds or greater. This primary indication addresses flea control through rapid elimination of existing adult fleas and prevention of new infestations over the monthly dosing period. The fast-acting formula begins killing fleas within six hours of administration, with one hundred percent flea kill achieved within twenty-four hours.

The medication is additionally indicated for the treatment and control of black-legged tick (Ixodes scapularis) infestations for one month in cats and kittens six months of age and older weighing two pounds or greater. Black-legged ticks are the most common tick species infesting cats in many geographic regions and are vectors for various tick-borne diseases. By providing effective tick control, lotilaner helps protect cats from both the direct effects of tick infestation and the potential disease transmission associated with tick bites.

Credelio Cat is commonly prescribed as part of treatment strategies for flea allergy dermatitis in cats. Flea allergy dermatitis results from hypersensitivity to flea saliva, causing severe skin irritation and itching even with minimal flea exposure. The rapid speed of kill provided by lotilaner is particularly valuable for flea-allergic cats, as fleas are eliminated before they can cause extensive feeding damage. Clinical studies demonstrated that lotilaner killed fleas before they could lay eggs, preventing subsequent environmental contamination and reinfestations that would otherwise perpetuate the allergic condition.

Veterinarians select lotilaner when oral administration is preferred over topical application, when cats have shown adverse reactions or intolerance to topical products, or when owner preference favors chewable tablet medication. The oral formulation eliminates concerns about topical product residue, application site reactions, or product wash-off from bathing or water exposure. Cats that resist topical application or groom excessively after topical treatment may be better candidates for oral lotilaner therapy.

The monthly dosing schedule of Credelio Cat aligns with common veterinary practice for preventive care timing, facilitating integration with other monthly parasite prevention protocols and wellness care schedules. This regularity may improve owner compliance compared to quarterly products, as monthly treatments become routine, though individual owner preferences vary. Treatment can begin at any time of year and continue year-round for continuous protection in areas with persistent flea and tick pressure.

Lotilaner (Credelio Cat) dosing is weight-based, with chewable tablets formulated to provide a minimum dose of 2.7 mg per pound (6 mg/kg) body weight. The medication is available in two tablet sizes: 12 mg tablets for cats weighing 2.0 to 4.0 pounds, and 48 mg tablets for cats weighing 4.1 to 17.0 pounds. Cats exceeding 17 pounds may receive an appropriate combination of tablets to achieve the minimum dose. Accurate cat weight determination ensures proper product selection and effective treatment.

Credelio Cat must be administered with food or within thirty minutes of feeding to ensure adequate absorption. Food enhances the oral bioavailability of lotilaner, and administration without food may result in reduced drug absorption and potentially decreased efficacy. Cat owners should ensure their cat has eaten recently or offer food along with the tablet to optimize treatment outcomes.

Administration involves giving the entire tablet orally once monthly. The flavored tablet may be offered directly to the cat, who may accept it as a treat, or it may be hidden in a small amount of food. In clinical studies, approximately twenty-one percent of doses were voluntarily consumed when offered by hand or in an empty bowl, an additional twenty-six percent were accepted when offered with food, and the remaining doses required direct oral placement. For cats that do not voluntarily accept the tablet, it may be placed directly in the mouth toward the back of the throat to facilitate swallowing.

Tablets are formulated for whole administration and should not be split or crushed. Content uniformity of partial tablets has not been established, and splitting is not recommended. If a cat requires a dose that falls between available tablet sizes, veterinary guidance should be sought regarding appropriate product selection. The manufacturer has developed multiple tablet sizes specifically to allow accurate dosing according to cat weight ranges.

For missed doses, Credelio Cat should be administered as soon as remembered, and monthly dosing should resume from that date. If a cat vomits within two hours of administration, redosing is recommended since adequate absorption may not have occurred. No doubled dosing is needed after a single missed treatment, as resuming the regular monthly schedule provides renewed protection going forward. Treatment can begin at any time of year and should continue without interruption in areas with ongoing flea and tick activity.

The effectiveness of Credelio Cat against black-legged ticks in kittens less than six months of age has not been evaluated, and the tick control indication applies only to cats meeting this age requirement. Flea control is approved for kittens as young as eight weeks old, provided they meet the minimum weight requirement of two pounds.

Lotilaner (Credelio Cat) is generally well-tolerated in cats, with adverse reactions occurring infrequently in clinical studies. The medication demonstrated a favorable safety profile across diverse feline populations, with most cats experiencing no adverse effects from treatment. Understanding potential side effects helps cat owners monitor their pets appropriately and recognize when veterinary consultation may be warranted.

The most frequently reported adverse reactions in cats receiving Credelio Cat include weight loss, rapid breathing (tachypnea), and vomiting. These effects were observed in clinical field studies and represent the most common documented reactions to the medication. The frequency of these effects was low, and most cases were mild and did not require treatment discontinuation. Weight changes should be monitored during ongoing therapy, and significant unexplained weight loss warrants veterinary evaluation.

Additional side effects reported less commonly include decreased appetite, diarrhea, lethargy, and behavioral changes. Gastrointestinal effects such as vomiting and diarrhea typically occur within the first day or two following administration and usually resolve without intervention. If gastrointestinal signs persist beyond forty-eight hours or are severe, veterinary consultation is advisable. Mild lethargy following administration generally resolves within a day and does not typically require treatment.

As a member of the isoxazoline class of medications, lotilaner carries class-associated warnings regarding potential neurological adverse reactions. The isoxazoline class has been associated with neurologic adverse reactions including tremors, ataxia (incoordination), and seizures in some animals. These neurological effects have been reported in cats receiving isoxazoline class drugs, including cases in cats without prior history of neurological disorders. While these reactions appear to be uncommon, their potential severity warrants awareness and appropriate monitoring.

Serious adverse reactions requiring immediate veterinary attention include seizures or convulsions, severe trembling or muscle twitching, inability to walk or severe incoordination, collapse, difficulty breathing, or signs of severe allergic reaction. While rare, any of these signs following Credelio Cat administration should prompt immediate veterinary evaluation. Cat owners should inform the veterinarian that the cat recently received an isoxazoline medication to facilitate appropriate assessment and treatment. Reporting suspected adverse drug reactions to the manufacturer and FDA contributes to ongoing safety monitoring of veterinary medications.

Lotilaner (Credelio Cat) has specific contraindications and use restrictions that guide appropriate patient selection. Understanding these limitations ensures safe medication use and helps identify situations where alternative treatments may be more appropriate for individual cats.

Credelio Cat is contraindicated in cats with known hypersensitivity to lotilaner or any of the inactive ingredients in the tablet formulation. Cats that have experienced allergic reactions or hypersensitivity to previous Credelio Cat doses should not receive additional treatments. Signs of hypersensitivity may include facial swelling, hives, severe itching, difficulty breathing, or anaphylactic reactions. Alternative flea and tick control methods should be selected for cats with documented lotilaner sensitivity.

The medication has not been evaluated for use in kittens younger than eight weeks of age for flea control, and this population should not receive Credelio Cat. For tick control, the product is not approved for kittens younger than six months of age, as effectiveness against black-legged ticks in younger kittens has not been evaluated. Cats must meet the minimum weight requirement of two pounds to receive treatment. Kittens below these age and weight thresholds should receive age-appropriate alternative flea and tick control products as recommended by their veterinarian.

The safety of Credelio Cat has not been established in breeding, pregnant, or lactating cats. Due to insufficient safety data in these populations, use is not recommended. Queen cats intended for breeding, pregnant cats, and nursing mothers should receive alternative flea and tick control methods. Veterinary consultation can identify appropriate products with established safety profiles for cats in reproductive stages.

Use with caution is advised in cats with a history of neurological disorders. The isoxazoline class of medications has been associated with neurological adverse events including tremors, ataxia, and seizures. While these events have occurred in cats without prior neurological history, cats with pre-existing seizure disorders or other neurological conditions may face elevated risk. Careful veterinary assessment of risks and benefits should guide treatment decisions for cats with neurological histories, and alternative flea and tick control options may be preferred in some cases.

Drug interaction studies specifically evaluating lotilaner (Credelio Cat) in cats indicate that the medication can be used safely with many commonly prescribed veterinary products. Clinical experience and field study data provide reassurance regarding concurrent medication use, though awareness of potential interactions supports safe prescribing practices.

In the United States field study for Credelio Cat, the medication was used concurrently with various other products including vaccines, anthelmintics (dewormers), antibiotics, and steroids without observed adverse reactions from concurrent use. This real-world evidence suggests that lotilaner can be safely integrated into comprehensive health management protocols that include multiple medications or preventive treatments.

No specific drug interactions have been documented in the product labeling or veterinary literature that would contraindicate lotilaner use with common feline medications. Cats receiving treatment for chronic conditions such as hyperthyroidism, diabetes, cardiac disease, or kidney disease have used Credelio Cat successfully, though individual veterinary assessment is always appropriate when adding new medications to an existing treatment regimen.

Theoretical considerations regarding isoxazoline medications and other neurologically active drugs warrant mention. Given lotilaner's mechanism of action involving GABA receptors in arthropods, concurrent use with medications that affect GABA signaling in mammals or lower seizure threshold theoretically merits attention. However, the selective toxicity of isoxazolines for arthropod versus mammalian receptors suggests this theoretical concern may have limited clinical relevance. Cats receiving anticonvulsant medications should be monitored when isoxazoline therapy is initiated, though specific interactions have not been documented.

Cat owners should inform their veterinarian about all medications, supplements, and preventive products their cat receives before starting Credelio Cat. This comprehensive medication history allows the veterinarian to evaluate potential interactions and make informed treatment recommendations. Any concerns about medication combinations should be discussed before initiating therapy. If adverse effects occur that might suggest a drug interaction, the veterinarian can assess whether medication adjustments are warranted.

Important precautions and warnings accompany Credelio Cat (lotilaner) use to ensure safe and effective treatment. Both veterinary professionals and cat owners should understand these considerations to optimize treatment outcomes and recognize situations requiring attention.

Credelio Cat must be administered with food to ensure adequate absorption. Administration without food significantly reduces oral bioavailability and may result in subtherapeutic drug levels and reduced efficacy. Cat owners should ensure their cat has eaten within thirty minutes before or after tablet administration. If a cat refuses food when medication is due, dosing should be delayed until the cat can be fed.

The neurological warning associated with isoxazoline class medications requires careful consideration when prescribing Credelio Cat. Neurological adverse reactions including tremors, ataxia, and seizures have been reported in cats receiving isoxazoline class drugs. These reactions have occurred in cats both with and without prior history of neurological disorders. Cat owners should monitor for any neurological signs following treatment and contact their veterinarian if concerns arise. Prompt veterinary evaluation is warranted if a cat shows tremors, seizures, difficulty walking, or other neurological abnormalities after receiving Credelio Cat.

Use with caution in cats with a history of neurological abnormalities is specifically advised in the product labeling. Cats with prior seizures, vestibular disease, or other neurological conditions may face elevated risk of adverse events. The decision to use Credelio Cat in these patients should involve careful veterinary assessment of benefits versus potential risks. Alternative flea and tick control methods without neurological warnings may be more appropriate for some cats with significant neurological histories.

Tablets should not be split, as content uniformity of partial tablets has not been established. Cats should receive whole tablets appropriate for their weight range. If a cat's weight falls between tablet size ranges or exceeds the maximum weight for available tablets, veterinary guidance should be sought regarding appropriate dosing.

If a cat vomits within two hours of receiving Credelio Cat, the dose should be repeated to ensure adequate drug absorption. Vomiting after this two-hour window typically does not require redosing, as sufficient absorption has likely occurred. Any concerns about treatment efficacy or adverse effects should be discussed with the prescribing veterinarian.

Proper storage and handling of Credelio Cat (lotilaner) maintains product integrity and ensures medication safety. Following recommended storage conditions preserves tablet effectiveness throughout the product's shelf life.

Credelio Cat tablets should be stored at controlled room temperature, typically between 68°F and 77°F (20°C and 25°C), with allowance for excursions between 59°F and 86°F (15°C and 30°C). The medication should be protected from excessive heat and humidity. Storage in areas prone to temperature extremes, such as vehicles, outdoor buildings, or near heating sources, should be avoided. Maintaining appropriate storage temperature ensures tablet stability and potency.

The medication should be kept in its original packaging until ready for use. The packaging is designed to protect tablets from moisture and environmental exposure. Individual tablet blisters should not be opened until the time of administration. Tablets removed from packaging should be used promptly rather than stored outside their protective packaging.

Credelio Cat should be stored securely out of reach of children and pets to prevent accidental ingestion. While the medication is designed for cats, accidental consumption by dogs, children, or other household members could cause adverse effects. The flavored tablets may be attractive to children or pets, making secure storage essential. A locked cabinet or location inaccessible to children and animals provides appropriate storage.

Handling precautions are minimal for Credelio Cat tablets, as the solid tablet form limits exposure during administration. Hands should be washed after handling the medication, particularly before eating or touching the face. Individuals with known sensitivities to isoxazoline compounds should consider wearing gloves when handling tablets. If accidental human ingestion occurs, medical advice should be sought.

Proper disposal of unused or expired medication protects both animals and the environment. Unused tablets should not be discarded in household trash where they might be accessible to animals or children. Many veterinary clinics and pharmacies accept unused medications for proper disposal. Community drug take-back programs may also accept veterinary medications. The product should not be flushed into wastewater systems. Following proper disposal procedures prevents environmental contamination and accidental exposure.

Lotilaner (Credelio Cat) is suitable for cats of all breeds, with the medication demonstrating efficacy and safety across diverse feline populations in clinical studies. The weight-based dosing system accommodates the natural size variation among different cat breeds, and no breed-specific dosing adjustments or contraindications have been identified.

Clinical field studies for Credelio Cat included cats representing a wide variety of breeds and coat types without documented breed-specific variations in response or tolerance. The medication's oral formulation means that coat characteristics do not affect drug delivery, unlike topical products where coat density or length might influence application or absorption. This makes Credelio Cat equally suitable for short-haired, long-haired, and hairless cat breeds.

The palatability studies conducted during product development demonstrated high acceptance rates across diverse cat populations. While individual cats vary in their willingness to accept oral medications, breed did not emerge as a significant factor in acceptance rates. The vanilla and yeast flavoring was designed to appeal broadly to feline taste and smell preferences, which are relatively consistent across breeds despite individual variation.

Size variations among cat breeds are accommodated through the weight-based dosing system. Small breeds such as Singapura or Cornish Rex may use the lower-dose tablet formulation, while larger breeds such as Maine Coons or Ragdolls receive appropriately higher doses. Cats at either extreme of the size spectrum should be weighed accurately to ensure proper product selection. Very large cats exceeding the maximum weight range for single tablets may require veterinary guidance on appropriate dosing.

Breeds with known predispositions to neurological conditions warrant individual consideration given the class-wide neurological warnings for isoxazoline medications. No breed-specific increased risk has been documented with lotilaner, but breeds reported to have higher prevalence of certain neurological conditions may warrant additional veterinary consideration. The decision to use Credelio Cat in any cat, regardless of breed, should involve appropriate assessment of individual health status and history. Age considerations apply equally across all breeds, with minimum age requirements of eight weeks for flea control and six months for tick control applying regardless of breed-typical size or development rate.

Lotilaner belongs to the isoxazoline class of ectoparasiticides, with several related medications and alternative approaches available for feline flea and tick control. Understanding the range of options helps veterinary professionals and cat owners select the most appropriate product for individual circumstances and preferences.

Fluralaner (Bravecto) is another isoxazoline medication available for cats, formulated as a topical solution rather than oral tablet. Fluralaner provides extended twelve-week protection against fleas and certain ticks with a single application, compared to lotilaner's monthly dosing. The choice between oral lotilaner and topical fluralaner often depends on owner preference regarding administration route and dosing frequency. Cats that resist topical application may be better candidates for oral lotilaner, while those difficult to medicate orally may prefer topical fluralaner.

Sarolaner is an isoxazoline available in combination with selamectin in the product Revolution Plus. This topical product provides monthly protection against fleas, ticks, heartworm, and certain intestinal parasites. The combination formulation offers comprehensive parasite protection in a single monthly application. Selamectin alone (Revolution) provides flea, heartworm, and some intestinal parasite control without the tick protection offered by sarolaner combination products.

Non-isoxazoline alternatives for feline flea and tick control include fipronil-based topical products (Frontline), imidacloprid and pyriproxyfen combinations (Advantage II), and various other topical formulations. These products offer alternatives for cats where isoxazoline medications are contraindicated due to neurological concerns or other factors. Efficacy profiles, spectrum of activity, and duration of protection vary among products, and veterinary guidance helps identify the most appropriate selection.

For cats unable to receive any systemic flea and tick medications, environmental treatment with insect growth regulators such as methoprene or pyriproxyfen combined with physical control measures provides an alternative approach. While this approach does not address parasites directly on the cat, comprehensive environmental treatment can significantly reduce flea populations in the home. Veterinary consultation ensures appropriate product selection when first-line treatments are not suitable, and no substitution of flea and tick products should occur without professional guidance.